Abstract:The present study aims to understand the mechanisms of mutant β-catenin in endometrial cancer (EC) patients with exon 3 CTNNB1 mutations. Endometrial cancer patients with exon 3 CTNNB1 mutations tend to be younger in age and have low cancer grades, but they exhibit worse recurrence-free survival than patients with similar clinical characteristics. It is unknown why EC patients with CTNNB1 mutations have worse survival. CTNNB1 encodes the protein β-catenin, which functions primarily at the cell membrane in the adherens junction complex and in the Wnt signaling pathway, where it localizes in the cytoplasm or nucleus. Exon 3 CTNNB1 mutations in EC are classically thought to promote nuclear localization of β-catenin. In this study, we conducted immunohistochemistry for β-catenin localization on 53 EC cases with an exon 3 CTNNB1 mutation from the UNCseq project. Surprisingly, 32 cases had primarily non-nuclear, either cytoplasmic or membranous, localization and 21 cases had primarily nuclear localization. Additionally, we identified 16 cases with intratumoral heterogeneity containing both nuclear and non-nuclear β-catenin localization. To investigate the functional consequences of this differential localization, we performed spatial transcriptomics using the Nanostring GeoMx Whole Transcriptome Analysis. Nuclear and non-nuclear regions of interest (ROI) were selected from 16 CTNNB1 mutant EC cases exhibiting heterogenous β-catenin localization within the same tissue (n=95 total ROIs). We hypothesize that β-catenin nuclear and non-nuclear ROIs will have differing transcriptional outputs in CTNNB1 mutant EC. Differential expression analysis of all ROIs yielded distinct transcriptional profiles based on localization of mutant β-catenin. Gene Set Enrichment Analysis revealed enrichment for Wnt-signaling and the epithelial-to-mesenchymal transition pathways in nuclear ROIs and enrichment for estrogen and androgen signaling pathways in non-nuclear ROIs. Hierarchical clustering of all ROIs yielded two genetically distinct clusters comprised of entirely nuclear or non-nuclear ROIs, with the exception of four ROIs. Higher expression of TACSTD2, encoding the protein Trop2, was enriched in the nuclear ROI cluster. Trop2 is the target of Sacituzumab Govitecan (SG), a drug conjugate with recent success in metastatic triple negative breast cancer patients. Additionally, studies have shown Trop2 to induce nuclear localization of β-catenin in other cancer types. Therefore, we hypothesize that CTNNB1 mutant EC patients with nuclear localization of β-catenin will respond better to SG treatment. To conclude, we established gene expression profiles for areas of nuclear and non-nuclear β-catenin in CTNNB1 mutant EC tissues and identified a novel gene with implications in mechanisms of β-catenin localization which may allow therapeutic targeting of advanced disease. Citation Format: Molly L. Parrish, Andrew B. Gladden, Russell R. Broaddus. Location, location, location: Why cellular localization of mutant β-catenin matters in endometrial cancer [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl) nr PR008.

β‐catenin expression in endometrioid type endometrial cancer: Expression patterns and impact on disease outcomes

CTHRC1 Overexpression Promotes Ectopic Endometrial Stromal Cell Proliferation, Migration and Invasion Via Activation of the Wnt/β-catenin Pathway

Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group

Aberrant nuclear β-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study

Abstract PR008: Location, location, location: Why cellular localization of mutant β-catenin matters in endometrial cancer

Expression of E-Cadherin and N-Cadherin in the Endocervix as a Predictive Factor in Patients with Endometrial Cancer

CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence

Prognostic Significance of Β-Catenin Expression in Patients with Non-Small Cell Lung Cancer: a Meta-Analysis

ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification

Detection of Beta-Catenin Protein Expression and Gene Mutation in Tumorigenesis of Endometrioid Adenocarcinoma

Cytoplasmic And/or Nuclear Expression of Β-Catenin Correlate with Poor Prognosis and Unfavorable Clinicopathological Factors in Hepatocellular Carcinoma: a Meta-Analysis.

Expression and clinical significance of GS,E-cadherin and β-catenin in hepatocellular carcinoma

Significance of E-cadherin, Β-Catenin, and Vimentin Expression As Postoperative Prognosis Indicators in Cervical Squamous Cell Carcinoma

Immunohistochemical Analysis Of Novel Biomarkers Cyclin D1, p53 And Ki67 In Endometrial Carcinoma: Clinicopathological Significance And Prognostic Value

Clinical Significance of Expression C-Ets-1 Endometrial Carcinoma Tissue

Prognostic Significance of β-Catenin in Relation to the Tumor Immune Microenvironment in Oral Cancer

Β-Catenin Overexpression in the Nucleus Predicts Progress Disease and Unfavourable Survival in Colorectal Cancer: A Meta-Analysis

Reduced Membranous and Ectopic Cytoplasmic Expression of Beta-Catenin Correlate with Cyclin D1 Overexpression and Poor Prognosis in Pancreatic Cancer

The prognostic value of tumor microenvironment in endometrioid type endometrial cancer: Effect of CD44 on oncologic outcome

Immunocytochemical Examination of Akt, Mtor and Pax-2 for Endometrial Carcinoma Through Thin-Layer Endometrial Cytology

High tumor infiltrating lymphocytes are associated with overall survival and good prognostic parameters in endometrial endometrioid carcinoma patients